Royal Bank of Canada
GANX icon

Royal Bank of Canada’s Gain Therapeutics GANX Stock Holding History

Royal Bank of Canada’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,500
Closed -$38K – 6961
2024
Q4 		$38K Buy
+17,500
New +$35.1K ﹤0.01% 5824
2024
Q3 		– Sell
-159
Closed – – 7056
2024
Q2 		$0 Sell
159
-248,341
-100% -$645K ﹤0.01% 7217
2024
Q1 		$937K Buy
248,500
+48,252
+24% +$200K ﹤0.01% 3511
2023
Q4 		$654K Sell
200,248
-9,752
-5% -$27.1K ﹤0.01% 4030
2023
Q3 		$689K Buy
210,000
+189,954
+948% +$720K ﹤0.01% 3767
2023
Q2 		$90K Sell
20,046
-18,954
-49% -$92.5K ﹤0.01% 5414
2023
Q1 		$188K Hold
39,000
– – ﹤0.01% 4682
2022
Q4 		$122K Sell
39,000
-86
-0.2% -$269 ﹤0.01% 5301
2022
Q3 		$127K Buy
39,086
+86
+0.2% +$323 ﹤0.01% 5145
2022
Q2 		$140K Sell
39,000
-11,000
-22% -$37.9K ﹤0.01% 5083
2022
Q1 		$205K Buy
50,000
+39,440
+373% +$165K ﹤0.01% 5065
2021
Q4 		$57K Buy
+10,560
New +$72.9K ﹤0.01% 6301

Other funds holding GANX

GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada's GANX Position: Q1 2025 in Review

Royal Bank of Canada sold out of Gain Therapeutics (GANX) in Q1 2025, closing a stake of 17,500 shares — an estimated $38K sold.

Royal Bank of Canada first reported a position in GANX in Q4 2021 and held it in 12 quarters. The position peaked at $937K in Q1 2024. 33 funds tracked by Wall St. Rank hold GANX as of Q1 2025.

  • Royal Bank of Canada reported no remaining Gain Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 17,500 Gain Therapeutics shares in Q1 2025, an estimated $38K.
  • Royal Bank of Canada first reported a position in Gain Therapeutics in Q4 2021 and held it in 12 quarters.
  • Royal Bank of Canada's Gain Therapeutics position peaked at $937K in Q1 2024.
  • 33 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2025.

Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.